Diagnosis of autoimmune hepatitis (AIH) may be challenging. However, early diagnosis is
important because immunosuppression is life‐saving. Diagnostic criteria of the International …

Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

Background Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in
the most severe form of viral hepatitis. There is no currently approved treatment. We …

Background & Aims Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary
disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). …

Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis
B patients under long‐term therapy with potent nucleos(t)ide analogues is currently unclear. …

Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating
the efficacy of pegylated interferon alpha (PEG‐IFNa) showed HDV RNA negativity rates …

Autoimmune hepatitis (AIH) is an unresolving progressive liver disease of unknown etiology
characterized by hypergammaglobulinemia, autoantibodies detection and interface hepatitis…

Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR ≥6 ng/ml …

… before with conventional therapy and received MMF as salvage therapy did not significantly
differ from that found in the present study in our treatment naive AIH patients (Dalekos and …